newsfilter
← Latest News
Business Wire·

AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

  • AtriCure, Inc. (ATRC) will participate in the Goldman Sachs 47th Annual Global Health Care Conference.
  • Management is scheduled for a fireside chat on Wednesday, June 10, 2026, at 8:40 a.m. Eastern Standard Time.
  • A live audio webcast of the event will be available via the "Investors" section of the company's website.
  • AtriCure provides technologies for atrial fibrillation treatment, left atrial appendage management, & post-operative pain management.
  • The Isolator® Synergy™ Ablation System is the first FDA-approved device for persistent Afib treatment.
  • AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices globally.
  • Hybrid AF™ Therapy is a minimally invasive procedure for long-standing persistent Afib patients.
  • cryoICE cryoSPHERE® & cryoXT® probes are cleared for temporary ablation of peripheral nerves to block pain in cardiac, thoracic, & amputation procedures.